Sequella, Inc.
PrivateLast Round
Convertible Debt
Oct 1, 2014
Total Funding Raised
$24.38M
Company Overview
Sequella, Inc. is a biopharmaceutical company that develops novel small-molecule antibiotics to treat drug-resistant bacterial, fungal, and parasitic infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sequella, Inc. Comparables
Compare Sequella, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DeNovaMed Inc. | 82% | |
| Microbiotix, Inc. | 81% | |
| Bioversys | 78% |
Sequella, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Oct 1, 2014 | ||||
| VC Round | Aug 23, 2011 | ||||
| Strategic | Apr 26, 2011 | ||||
| Grant | Apr 4, 2011 | ||||
| Grant | Oct 28, 2010 | ||||
VC Round | Oct 4, 2007 |
Sequella, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| Bundesministerium für Bildung und Forschung | Grant |
| European and Developing Countries Clinical Trials Partnership | Grant |
| Medical Research Council | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 4, 2011
$4.6M grant from the National Institute of Allergy and Infectious Diseases.
- Oct 28, 2010
$17M grant round led by European and Developing Countries Clinical Trials Partnership.
Sequella, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Sequella, Inc.'s valuation, stock price, and market status.
Is Sequella, Inc. a public or private company?
Sequella, Inc. is a private company.
What is the current stock price of Sequella, Inc.?
Sequella, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Sequella, Inc. worth (valuation)?
Valuation information for Sequella, Inc. is not publicly available.
Can I buy Sequella, Inc. stock?
Sequella, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Sequella, Inc.'s last funding round?
Sequella, Inc.'s most recent funding round was Convertible Debt on October 1, 2014.
Who are the main investors in Sequella, Inc.?
Key investors in Sequella, Inc. include National Institute of Allergy and Infectious Diseases, European and Developing Countries Clinical Trials Partnership.
Will Sequella, Inc. IPO soon?
No public IPO plans have been announced for Sequella, Inc..
How can I track Sequella, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sequella, Inc.'s secondary market activity and sign up for updates.